Literature DB >> 8024611

Local anti-type II collagen antibody production in rheumatoid arthritis synovial fluid. Evidence for an HLA-DR4-restricted IgG response.

J Rönnelid1, J Lysholm, A Engström-Laurent, L Klareskog, B Heyman.   

Abstract

OBJECTIVE: To investigate the production of type II collagen (CII) antibodies in the synovial fluid (SF) of rheumatoid arthritis (RA) patients, and to examine the HLA dependence of this local production.
METHODS: The ELISPOT method was used for enumerating anti-CII-reactive cells. Serologic tissue typing was performed.
RESULTS: Anti-CII-reactive cells were found in the SF of 16 of 31 patients, but not in any of the peripheral blood samples obtained in parallel. SF anti-CII antibody production showed no correlation with clinical parameters, but its frequency increased significantly with age. The IgG anti-CII response occurred exclusively in patients who were positive for HLA-DR4 and was significantly associated with DR4.
CONCLUSION: Anti-CII production may be important in local immune complex formation. The indirect demonstration of a DR4-restricted T cell response to CII is an indication of a pathogenetic role of collagen autoimmunity in RA.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8024611     DOI: 10.1002/art.1780370707

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  38 in total

Review 1.  [Rheumatology update. Current knowledge of etiology, pathophysiology, diagnosis, and therapy of selected arthritic disorders. Part I: pathogenesis and differential diagnosis].

Authors:  G Hein; P Oelzner; H Sprott; B Manger
Journal:  Med Klin (Munich)       Date:  1999-09-15

2.  Serum antibodies to oral anaerobic bacteria in patients with rheumatoid arthritis.

Authors:  Mesut Ogrendik; Siranus Kokino; Ferda Ozdemir; Philip S Bird; Stephen Hamlet
Journal:  MedGenMed       Date:  2005-06-16

3.  Definition of MHC and T cell receptor contacts in the HLA-DR4restricted immunodominant epitope in type II collagen and characterization of collagen-induced arthritis in HLA-DR4 and human CD4 transgenic mice.

Authors:  E C Andersson; B E Hansen; H Jacobsen; L S Madsen; C B Andersen; J Engberg; J B Rothbard; G S McDevitt; V Malmström; R Holmdahl; A Svejgaard; L Fugger
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

4.  Ro/SS-A- and La/SS-B-reactive B lymphocytes in peripheral blood of patients with Sjögren's syndrome.

Authors:  A Halse; M Wahren-Herlenius; R Jonsson
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

5.  B cell-deficient mice do not develop type II collagen-induced arthritis (CIA).

Authors:  L Svensson; J Jirholt; R Holmdahl; L Jansson
Journal:  Clin Exp Immunol       Date:  1998-03       Impact factor: 4.330

6.  Type II collagen serology: a guide to clinical responsiveness to oral tolerance?

Authors:  U Gimsa; J Sieper; J Braun; N A Mitchison
Journal:  Rheumatol Int       Date:  1997       Impact factor: 2.631

7.  Ro/SS-A-reactive B lymphocytes in salivary glands and peripheral blood of patients with Sjögren's syndrome.

Authors:  A Halse; J B Harley; U Kroneld; R Jonsson
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

Review 8.  Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis.

Authors:  Anca I Catrina; Camilla I Svensson; Vivianne Malmström; Georg Schett; Lars Klareskog
Journal:  Nat Rev Rheumatol       Date:  2016-12-15       Impact factor: 20.543

Review 9.  The association between rheumatoid arthritis and periodontal disease.

Authors:  Jacqueline Detert; Nicole Pischon; Gerd R Burmester; Frank Buttgereit
Journal:  Arthritis Res Ther       Date:  2010-10-22       Impact factor: 5.156

10.  Collagen-specific T-cell repertoire in blood and synovial fluid varies with disease activity in early rheumatoid arthritis.

Authors:  Francesco Ria; Romina Penitente; Maria De Santis; Chiara Nicolò; Gabriele Di Sante; Massimiliano Orsini; Dario Arzani; Andrea Fattorossi; Alessandra Battaglia; Gian Franco Ferraccioli
Journal:  Arthritis Res Ther       Date:  2008-11-17       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.